Fabrazyme
page
1
of
1
Sanofi's Genzyme wins approval for Framingham site
Jan 24, 2012 01:50 EST
PARIS (Reuters) - Sanofi's unit Genzyme said on Tuesday it had won U.S. regulatory approval for its Framingham, U.S.-based plant that will produce Fabrazyme, aiming to get patients back on their required dosages of the rare disease drug worldwide this year.
Sanofi CEO says drug industry undervalued
Sep 20, 2011 07:31 EDT
NEW YORK (Reuters) - Sanofi SA's <SASY.PA> chief executive has already put his company's patent expiration woes in the rear view mirror and believes that the French drugmaker and the pharmaceutical industry are undervalued.
Shire CEO sees diabetes surge buoying Dermagraft
Sep 16, 2011 07:49 EDT
NEW YORK (Reuters) - Shire Plc <SHP.L> sees a strong market for its recently acquired Dermagraft skin substitute due to surging rates of diabetes that can cause foot ulcers in a significant number of patients, according to its chief executive.
Sanofi ups EPS but Genzyme seen missing milestone
Jul 28, 2011 02:47 EDT
PARIS (Reuters) - French drugmaker Sanofi <SASY.PA> raised its earnings forecast for 2011 now that Genzyme is part of its business, but said the U.S. biotech would likely miss its first milestone fee due to supply constraints of one of its key drugs.
Sanofi wins control of Genzyme, CVRs fetch $2.35
Apr 04, 2011 10:39 EDT
PARIS/LONDON (Reuters) - Certificates used by Sanofi-Aventis SA to win Genzyme Corp started trading at a steep discount to their best-case value on Monday after the French drugmaker gained control of the biotech group.
Sanofi wins control of Genzyme, CVRs fetch $2.35
Apr 04, 2011 10:39 EDT
PARIS/LONDON (Reuters) - Certificates used by Sanofi-Aventis SA to win Genzyme Corp started trading at a steep discount to their best-case value on Monday after the French drugmaker gained control of the biotech group.
Genzyme meets first consent decree deadline
Nov 24, 2010 11:16 EST
BOSTON (Reuters) - Genzyme Corp <GENZ.O> has met the first in a series of deadlines imposed by U.S. regulators for fixing problems at its Boston plant, a milestone that could bolster the biotech company's argument that it is worth more than the $18.5 billion being offered by French drugmaker Sanofi-Aventis SA <SASY.PA>.
Genzyme makes case for demanding higher Sanofi bid
Oct 22, 2010 18:13 EDT
NEW YORK (Reuters) - Genzyme Corp made its case for why it is worth more than Sanofi-Aventis's $18.5 billion offer, forecasting 2011 profit above Wall Street estimates and sales of $3 billion for its experimental multiple sclerosis drug.
Genzyme profit up, Cerezyme sales nearly double
Oct 20, 2010 13:32 EDT
BOSTON (Reuters) - Genzyme Corp <GENZ.O>, which is fending off a hostile bid from French drugmaker Sanofi-Aventis SA <SASY.PA>, said third-quarter earnings quadrupled as it increased shipments of its biggest-selling drug.
Sanofi-Aventis launches Genzyme takeover battle
Oct 04, 2010 15:05 EDT
Sanofi-Aventis goes hostile with $69/share offer for US biotech company Genzyme. France's Sanofi-Aventis on Monday launched an $18.5 billion hostile takeover attempt for Genzyme Corp., escalating the battle after the U.S. biotech company's management twice rejected its offer.
Sanofi-Aventis launches Genzyme takeover battle
Oct 04, 2010 15:04 EDT
France's Sanofi-Aventis on Monday launched an $18.5 billion hostile takeover attempt for Genzyme Corp., escalating the battle after the U.S. biotech company's management twice rejected its offer.
Sanofi-Aventis launches Genzyme takeover battle
Oct 04, 2010 09:54 EDT
Sanofi-Aventis goes hostile with $69/share offer for US biotech company Genzyme. France's Sanofi-Aventis on Monday launched an $18.5 billion hostile takeover offer for Genzyme Corp., stepping up its effort to capture the U.S. biotech company's promising drugs for high cholesterol and lucrative treatments for rare genetic disorders.
Sanofi CEO sees reasonable chance of Genzyme deal
Sep 15, 2010 09:31 EDT
PARIS (Reuters) - Sanofi-Aventis <SASY.PA> sees a reasonable chance of buying U.S. biotech Genzyme <GENZ.O> at a fair price, but expects it will take some time to agree a deal that would further diversify the French drugmaker and strengthen its U.S. foothold.
Sanofi-Aventis sticking to first offer for Genzyme
Sep 09, 2010 18:25 EDT
Sanofi-Aventis sticking to $69-a-share offer for Genzyme, as Sanofi CEO courts shareholders. French drugmaker Sanofi-Aventis SA is sticking to its original offer of $69 a share to buy U.S. biotech company Genzyme Corp., a Sanofi spokesman said Thursday.
Sanofi-Aventis sticking to first offer for Genzyme
Sep 09, 2010 17:05 EDT
French drugmaker Sanofi-Aventis SA is sticking to its original offer of $69 a share to buy U.S. biotech company Genzyme Corp., a Sanofi spokesman said Thursday.
Genzyme CEO open to sale, not at $69 a share
Sep 01, 2010 05:22 EDT
BOSTON (Reuters) - Genzyme Corp <GENZ.O> Chief Executive Henri Termeer said he is willing to sell the company he built up over 25 years, but not for $69 a share.
Genzyme rejects Sanofi offer as long battle looms
Aug 31, 2010 12:02 EDT
PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.
Genzyme rejects Sanofi-Aventis offer
Aug 30, 2010 17:08 EDT
Genzyme rejects Sanofi-Aventis' $18.5 billion buyout offer, terms bid 'opportunistic'. Biotechnology company Genzyme Corp. said Monday it rejected Sanofi-Aventis SA's $18.5 billion buyout offer because it undervalues the company.
Genzyme rejects Sanofi-Aventis offer
Aug 30, 2010 17:07 EDT
Biotechnology company Genzyme Corp. said Monday it rejected Sanofi-Aventis SA's $18.5 billion buyout offer because it undervalues the company.
Genzyme rejects Sanofi offer as long battle looms
Aug 30, 2010 16:06 EDT
PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.
Facts from the Wikipedia page:
| Galactosidase, alpha | |||
|---|---|---|---|
 PDB rendering based on 1r46. | |||
| Available structures | |||
| 1r46, 1r47 | |||
| Identifiers | |||
| Symbols | GLA; GALA | ||
| External IDs | OMIM: 301500 MGI: 1347344 HomoloGene: 55441 GeneCards: GLA Gene | ||
| RNA expression pattern | |||
 | |||
| More reference expression data | |||
| Orthologs | |||
| Species | Human | Mouse | |
| Entrez | 2717 | 11605 | |
| Ensembl | ENSG00000102393 | ENSMUSG00000031266 | |
| UniProt | P06280 | Q3TLY5 | |
| RefSeq (mRNA) | NM_000169 | NM_013463 | |
| RefSeq (protein) | NP_000160 | NP_038491 | |
| Location (UCSC) | Chr X: 100.54 - 100.55 Mb | Chr X: 129.93 - 129.95 Mb | |
| PubMed search | [1] | [2] | |
